# National Vision Holdings, Inc.: overview

EYE · Nasdaq · CIK 1710155 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 2

Pages: [Overview](/companies/eye.md) · [Financials](/companies/eye/financials.md) · [Filings](/companies/eye/filings.md) · [Insiders](/companies/eye/insiders.md)

Latest reported revenue: [$498.8m](/filings/0001628280-26-056493.md) for Q2 FY2026, three months to 2026-07-04, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-056493).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [452](/filings/0001628280-25-049891.md) | [437](/filings/0001710155-25-000011.md) | [510](/filings/0001628280-26-034824.md) | [486](/filings/0001628280-26-056493.md) | [487](/filings/0001628280-25-049891.md) | [503 d](/filings/0001628280-26-014379.md) | [544](/filings/0001628280-26-034824.md) | [499](/filings/0001628280-26-056493.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(2.0%)](/filings/0001628280-25-049891.md) | [(5.8%)](/filings/0001710155-25-000011.md) | [5.1%](/filings/0001628280-26-034824.md) | [3.4%](/filings/0001628280-26-056493.md) | [2.0%](/filings/0001628280-25-049891.md) | [1.3% d](/filings/0001628280-26-014379.md) | [8.3%](/filings/0001628280-26-034824.md) | [4.3%](/filings/0001628280-26-056493.md) |
| Net margin | % | [(1.9%)](/filings/0001628280-25-049891.md) | [(6.5%)](/filings/0001710155-25-000011.md) | [2.8%](/filings/0001628280-26-056493.md) | [1.8%](/filings/0001628280-26-056493.md) | [0.7%](/filings/0001628280-25-049891.md) | [0.7% d](/filings/0001628280-26-014379.md) | [5.7%](/filings/0001628280-26-056493.md) | [2.5%](/filings/0001628280-26-056493.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001628280-25-049891.md) | [(0.36)](/filings/0001710155-25-000011.md) | [0.18](/filings/0001628280-26-034824.md) | [0.11](/filings/0001628280-26-056493.md) | [0.04](/filings/0001628280-25-049891.md) | not reported | [0.38](/filings/0001628280-26-034824.md) | [0.15](/filings/0001628280-26-056493.md) |
| Free cash flow | $m | [4.1 d](/filings/0001628280-25-049891.md) | [(1.7) d](/filings/0001628280-26-014379.md) | [12.0](/filings/0001628280-26-034824.md) | [42.4 d](/filings/0001628280-26-056493.md) | [30.3 d](/filings/0001628280-25-049891.md) | [(11.2) d](/filings/0001628280-26-014379.md) | [44.1](/filings/0001628280-26-034824.md) | [(14.1) d](/filings/0001628280-26-056493.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2022-01-01) | FY2022 (2022-12-31) | FY2023 (2023-12-30) | FY2024 (2024-12-28) | FY2025 (2026-01-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,080](/filings/0001710155-24-000018.md) | [1,645](/filings/0001710155-25-000011.md) | [1,756](/filings/0001628280-26-014379.md) | [1,823](/filings/0001628280-26-014379.md) | [1,987](/filings/0001628280-26-014379.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [8.4%](/filings/0001710155-24-000018.md) | [3.2%](/filings/0001710155-25-000011.md) | [1.4%](/filings/0001628280-26-014379.md) | [(0.6%)](/filings/0001628280-26-014379.md) | [3.0%](/filings/0001628280-26-014379.md) |
| Net margin | % | [6.2%](/filings/0001710155-24-000018.md) | [2.6%](/filings/0001710155-25-000011.md) | [(3.8%)](/filings/0001628280-26-014379.md) | [(1.6%)](/filings/0001628280-26-014379.md) | [1.5%](/filings/0001628280-26-014379.md) |
| Diluted EPS | $ per share | [1.43](/filings/0001710155-24-000018.md) | [0.52](/filings/0001710155-25-000011.md) | [(0.84)](/filings/0001628280-26-014379.md) | [(0.36)](/filings/0001628280-26-014379.md) | [0.37](/filings/0001628280-26-014379.md) |
| Free cash flow | $m | [163](/filings/0001710155-24-000018.md) | [5.7](/filings/0001710155-25-000011.md) | [58.3](/filings/0001628280-26-014379.md) | [38.1](/filings/0001628280-26-014379.md) | [73.5](/filings/0001628280-26-014379.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eye/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2019-08-12 | [KKR Fund Holdings L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 9,149,908 | $30.52 | $279.3m | [Form 4](/filings/0001140361-19-015057.md) |
| 2018-11-19 | [KKR Fund Holdings L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 10,054,259 | $40.20 | $404.2m | [Form 4](/filings/0001140361-18-043576.md) |
| 2018-08-02 | [KKR Fund Holdings L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 1,742,007 | $38.2594 | $66.6m | [Form 4](/filings/0001140361-18-035618.md) |
| 2018-07-30 | [KKR Fund Holdings L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 11,452,321 | $38.2594 | $438.2m | [Form 4](/filings/0001140361-18-034859.md) |
| 2018-03-26 | [KKR Fund Holdings L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 1,444,822 | $31.68 | $45.8m | [Form 4](/filings/0001140361-18-015537.md) |
| 2018-03-19 | [KKR Fund Holdings L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 9,632,145 | $31.68 | $305.1m | [Form 4](/filings/0001140361-18-014475.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $230.3m | 12,114,392 |  | Added +578,754 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $145.8m | 7,669,853 |  | Added +2,173,887 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $103.3m | 5,432,564 |  | Reduced −314,419 |
| [WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC](/funds/1644956.md) | 2026-06-30 | $90.2m | 4,747,422 |  | Added +521,656 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $77.4m | 4,070,392 |  | Added +2,979,948 |
| [Engine Capital Management, LP](/funds/1665590.md) | 2026-06-30 | $66.9m | 3,520,944 |  | Added +3,511,406 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $65.9m | 3,465,157 |  | Added +287,081 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $64.6m | 3,400,130 |  | Reduced −37,737 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $64.3m | 3,384,805 |  | Added +322,614 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $59.9m | 3,148,704 |  | Added +1,849,624 |

## Recent filings

[All 675 filings](/companies/eye/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 08:20 ET | [10-Q](/filings/0001628280-26-056493.md) | Quarterly report, period 2026-07-04 | 0001628280-26-056493 |
| 2026-08-12 | 06:03 ET | [8-K](/filings/0001628280-26-055930.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-055930 |
| 2026-06-22 | 16:11 ET | [8-K](/filings/0001628280-26-044630.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-044630 |
| 2026-06-03 | 08:00 ET | [8-K](/filings/0001628280-26-040046.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-040046 |
| 2026-05-14 | 08:37 ET | [10-Q](/filings/0001628280-26-034824.md) | Quarterly report, period 2026-04-04 | 0001628280-26-034824 |
| 2026-05-13 | 06:06 ET | [8-K](/filings/0001628280-26-034360.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-034360 |
| 2026-05-04 | 06:01 ET | [DEF 14A](/filings/0001140361-26-018642.md) | Proxy statement, period 2026-06-17 | 0001140361-26-018642 |
| 2026-03-04 | 06:07 ET | [10-K](/filings/0001628280-26-014379.md) | Annual report, period 2026-01-03 | 0001628280-26-014379 |
| 2026-03-04 | 06:02 ET | [8-K](/filings/0001628280-26-014376.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-014376 |
| 2025-12-16 | 16:30 ET | [8-K](/filings/0001104659-25-121608.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-25-121608 |

## Latest annual report

[Form 10-K for the fiscal year ended Jan 3, 2026](/filings/0001628280-26-014379.md), filed Mar 4, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1710155
- Tickers: EYE
- Exchange: Nasdaq
- SIC code: 3851 Ophthalmic Goods
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 13:56 ET. No prices; not investment advice.